Highland Capital Management LLC acquired a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 23,105 shares of the exchange traded fund’s stock, valued at approximately $2,283,000.
Other hedge funds also recently bought and sold shares of the company. ORG Partners LLC purchased a new stake in shares of SPDR S&P Biotech ETF in the 2nd quarter valued at about $40,000. ORG Wealth Partners LLC bought a new stake in SPDR S&P Biotech ETF during the third quarter valued at approximately $44,000. Waldron Private Wealth LLC purchased a new position in SPDR S&P Biotech ETF in the 3rd quarter worth approximately $54,000. Resources Management Corp CT ADV grew its stake in SPDR S&P Biotech ETF by 30.3% in the 2nd quarter. Resources Management Corp CT ADV now owns 593 shares of the exchange traded fund’s stock worth $55,000 after buying an additional 138 shares in the last quarter. Finally, Lynx Investment Advisory bought a new position in shares of SPDR S&P Biotech ETF in the 2nd quarter worth $58,000.
SPDR S&P Biotech ETF Stock Performance
NYSEARCA XBI opened at $97.15 on Friday. SPDR S&P Biotech ETF has a 52-week low of $63.80 and a 52-week high of $103.52. The company has a fifty day moving average of $99.14 and a 200-day moving average of $94.62. The company has a market capitalization of $7.40 billion, a P/E ratio of 11.47 and a beta of 1.11.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- How to Invest in the Best Canadian Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Insider Trades May Not Tell You What You Think
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What is Insider Trading? What You Can Learn from Insider Trading
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.